FibroLife® Fibroblast Basal Medium – Somata

Skip to content

Bioequivalence
Community
Investors

Now providing Mesenchymal cell-based immunomodulation for Covid19-induced hypercytokinemia. Call us to learn more

Genesis Biopharmaceuticals

Covid-19
- Clinical Trials
- Products
  - Ventilator
Treatments
Biopharmaceuticals
Services
- Bioequivalence
- Pharmacokinetics
Discoveries
- Multiple Sclerosis
- COVID-19

Search for:

Fibroblast Media

FibroLife® Fibroblast Basal Medium

- Nov. 08, 2017

FibroLife® Fibroblast Basal Medium

Written by Mansi Dua

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Δ

https://www.facebook.com/somatagenesis

PO Box 66 Albion ID 83311, USA

International +91 992 149 6595

USA +1 646 583 1660

info@somatagenesis.com

Neutrojen
Somajen
Stem cells
Bioequivalence
Contact
COVID-19
Multiple Sclerosis Research

Copyright © 2025 Somata Genesis, Inc. | 416, Burlington Tower, Business Bay, Dubai, United Arab Emirates

Facebook
LinkedIn
Twitter